Abstracts tagged "osteoporosis"

Abstract Number: 0121 • ACR Convergence 2020
Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women
Rashmi Dhital¹, P. Daniel Nicholas², Gregory Emkey³ and Anthony Donato², ¹Reading Hospital and Medical Center, West Reading, ²Reading Hospital and Medical Center, West Reading, PA, ³Reading Hospital and Medical Center, Reading, PA
Background/Purpose: Total joint replacement (TJR) is the standard surgical treatment for end-stage hip and knee osteoarthritis (OA). Patient optimization may limit the need for early…
Abstract Number: 0926 • ACR Convergence 2020
Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort
Sina Famenini¹, Jamie Perin², Kristin Wipfler³, Kaleb Michaud⁴ and Zsuzsanna McMahan⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²JHUSPH, Baltimore, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Johns Hopkins University, Baltimore
Background/Purpose:Systemic sclerosis (SSc) is associated with several risk factors for osteoporosis and fractures due to malabsorption or malnutrition, physical disability, chronic inflammation, and use of…
Abstract Number: 0104 • ACR Convergence 2020
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Attila Hamar¹, Anita Pusztai², Edit Végh¹, Ágnes Horváth¹, Katalin Gulyás¹, Szilvia Szamosi¹, Zsófia Pethő¹, Nóra Bodnár¹, Boglárka Soós¹, Monika Czókolyová¹, Sándor Szántó¹, Gabriella Szűcs¹, Harjit Bhattoa¹, Gábor Nagy¹, Gábor Tajti¹, Andrea Domján¹, Katalin Hodosi¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary
Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
Abstract Number: 0122 • ACR Convergence 2020
Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry
Nitasha Khullar¹, Lang Chen², Jeffrey R Curtis³, Joshua Baker⁴, Huifeng Yun³, Andreas Reimold⁵ and Maria (Maio) Danila⁶, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Many effective medications are available for osteoporosis treatment. However how rheumatologists use these therapies is not well understood, particularly in patients with concomitant rheumatologic…
Abstract Number: 0966 • ACR Convergence 2020
Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3
Zheni Stavre¹, JungMin Kim², Jae-Hyuck Shim² and Ellen Gravallese³, ¹University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to local and systemic bone loss. TNF is a key mediator of bone loss,…
Abstract Number: 0105 • ACR Convergence 2020
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Balázs Juhász¹, Katalin Gulyás¹, Ágnes Horváth¹, Edit Végh¹, Anita Pusztai², Ágnes Szentpétery³, Zsófia Pethő¹, Nóra Bodnár¹, Attila Hamar¹, Levente Bodoki¹, Harjit Bhattoa¹, Éva Szekanecz¹, Katalin Hodosi¹, Andrea Domján¹, Szilvia Szamosi¹, Csaba Horváth⁴, Sándor Szántó¹, Gabriella Szűcs¹, Hennie Raterman⁵, Oliver FitzGerald⁶ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Semmelweis University, Budapest, Hungary, ⁵Northwest Clinics, Alkmaar, Netherlands, ⁶Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…
Abstract Number: 0123 • ACR Convergence 2020
Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention
Matthew White¹ and Luke Barre², ¹Roger Williams Medical Center, Providence, RI, ²Hawthorn Medical Associates, Dartmouth, MA
Background/Purpose: Aromatase inhibitors (AI) are frequently used in hormone receptor-positive breast cancer, which encompasses nearly 75% of all breast cancers. By preventing peripheral estrogen production,…
Abstract Number: 1206 • ACR Convergence 2020
Associations of Vascular and Bone Status in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Anita Pusztai¹, Attila Hamar², Monika Czókolyová², Katalin Gulyás², Ágnes Horváth², Edit Végh², Zsófia Pethő², Szilvia Szamosi², Emese Balogh², Nóra Bodnár², Ágnes Szentpétery³, Harjit Bhattoa², György Kerekes², Balázs Juhász², Éva Szekanecz², Katalin Hodosi², Andrea Domján², Sándor Szántó², Hennie Raterman⁴, Willem Lems⁵, Zoltán Szekanecz² and Gabriella Szűcs², ¹University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ²University of Debrecen, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Northwest Clinics, Alkmaar, Netherlands, ⁵Amsterdam Rheumatology and Immunology Centre, Amsterdam, Netherlands
Background/Purpose: Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the ageing population, even more in patients with inflammatory rheumatic diseases, such as…
Abstract Number: 0106 • ACR Convergence 2020
A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia
Qianrong Xie¹, Yue Chen², Yimei Hu³, Fanwei Zeng⁴, Pingxi Wang⁴, Lin Xu⁵, Jianhong Wu⁶, Jie Li¹, Jing Zhu⁷, Ming Xiang⁸ and Fanxin Zeng⁹, ¹Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China (People's Republic), ²Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China (People's Republic), ³Department of Orthopedics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China (People's Republic), ⁴Department of bone disease, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁵Department of medical imaging, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁶Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁷Department of Rheumatology and Immunology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China (People's Republic), ⁸Department of Orthopedics, Sichuan Provincial Orthopedic Hospital, Chengdu, China (People's Republic), ⁹Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic)
Background/Purpose: To discriminate osteoporosis and osteopenia using a quantitative computed tomography (QCT) radiomics signatures and clinical variables.Methods: This retrospective study enrolled 635 patients with QCT images and clinical characteristics from November…
Abstract Number: 0124 • ACR Convergence 2020
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Hugo Raposo¹, Daniel Lindstrom¹ and Jonathan Cheah², ¹University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Shrewsbury, MA
Background/Purpose: Denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) is a popular choice for osteoporosis therapy. However,…
Abstract Number: 1336 • ACR Convergence 2020
Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Eric Toussirot¹, Renaud Winzenrieth², Maxime Desmarets³, Daniel Wendling⁴, Francois Aubin⁵ and Gilles Dumoulin⁶, ¹CIC biotherapies, Besançon University Hospital, Besançon, France, ²GALGO medical, Barcelona, Spain, ³INSERM CIC-1431, Besancon, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Dermatology, Besancon, France, ⁶Laboratoire de Biochimie Médicale, UF de Biochimie Endocrinienne et Métabolique, Besancon, France
Background/Purpose: current data regarding areal bone mineral density (aBMD) in patients with psoriasis (PsO) or psoriatic arthritis (PsA) are conflicting. Results on Trabecular Bone Score…
Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…
Abstract Number: 0125 • ACR Convergence 2020
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Catherine Teskin¹ and Hiba Sayed², ¹Christiana Care, Wilmington, ²Christiana Care, wilmington, DE
Background/Purpose: Osteoporosis is a major cause of morbidity and mortality in the United States. The USPSTF recommends screening all women age 65 and older or…
Abstract Number: 1337 • ACR Convergence 2020
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Olga Compán¹, Maria Elisa Acosta², Sonia Pastor², Guadalupe Manzano Canabal², Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Noelia Cubino², Ricardo Usategui⁵, Rogelio Gonzalez Sarmiento⁵, Olga Martinez Gonzalez⁶, Ana Isabel Turrión², Javier Del Pino-Montes² and Carlos Montilla Morales², ¹Hospital Universitario de Salamanca, ´Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, ⁶Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…
Abstract Number: 0108 • ACR Convergence 2020
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
Anastasia- Vasiliki Madenidou¹ and Marwan Bukhari², ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Barrow-in-Furness, United Kingdom, ²Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Currently, Dual-Energy X-ray Absorptiometry (DEXA) scans are used to determine fracture risk by calculating Bone Mineral Density (BMD). It is well established that body…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].